Reference Infliximab, Biosimilar Equivalent for Crohn ' s Disease

TUESDAY, Dec. 11, 2018 -- CT-P13, which is a biosimilar of the reference product (RP) infliximab, has equivalent effectiveness for infliximab-naive patients with Crohn ' s disease (CD), according to a study published online Dec. 11 in the Annals of...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news